PORTAGE BIOTECH INC. (PRTG) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
PRTG currently has 6.35M outstanding shares. with significant dilution risk as 7.66M authorized shares could dilute existing holders by 120.7%. The company has significantly diluted shareholders by 296.42% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Dec 03, 2025 |
F-3 filing: This is an F-3 filing for a shelf offering of ordinary shares and debt securities, with a total proposed amount of $420,690,000. |
6.3M | 7.7M |
| Nov 06, 2025 |
F-3 filing: An F-3 filing indicating the offering of ordinary shares by a selling shareholder, with up to 189,719 shares offered and 6,349,197 ordinary shares outstanding as of October 20, 2025. |
6.3M | 7.7M |
| Oct 10, 2025 |
F-3 filing: This is an F-3 filing for an offering of Ordinary Shares by Selling Shareholders. |
5.9M | 7.5M |
| Jul 25, 2025 |
20-F filing | 2.3M shares outstanding |
2.3M | 0 |
| May 05, 2025 |
F-3 filing: The filing is an F-3 form, indicating a shelf registration for potential future offerings of common stock. The company may offer and sell the securities from time to time at fixed prices, at prevailing market prices or at negotiated prices, pursuant to one or more of the methods described in the filing. |
990K | 0 |
| Aug 23, 2024 |
POS AM filing: This POS AM filing relates to an offering of ordinary shares by selling shareholders, following the issuance upon exercise of warrants. The company will not receive any proceeds from the sale of shares but will receive proceeds from any warrants exercised for cash. |
990K | 0 |
| Aug 14, 2024 |
20-F filing | 19.8M shares outstanding |
20M | 9.6M |
| Oct 31, 2023 |
F-1 filing: This F-1 filing pertains to an offering of up to 9,631,580 ordinary shares by selling shareholders, following issuance upon exercise of warrants. The company will not receive any proceeds from the sale of these shares, although they will receive proceeds from any warrants exercised for cash. |
21M | 9.6M |
| Jul 31, 2023 |
20-F filing | 17.8M shares outstanding |
18M | 0 |
| Aug 01, 2022 |
20-F filing | 16.9M shares outstanding |
17M | 0 |
| Jul 29, 2021 |
20-F filing | 13.3M shares outstanding |
13M | 0 |
| Feb 24, 2021 |
F-3 filing: Portage Biotech Inc. is offering ordinary shares with an aggregate offering price of up to $50,000,000 through Cantor Fitzgerald & Co. as a sales agent in an "at the market offering." |
12M | 0 |
| Aug 17, 2020 |
20-F filing | 11.8M shares outstanding |
12M | 0 |